shares of Principia Biopharma Inc (PRNB) on
Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. The company is headquartered in South San Francisco, California and currently employs 90 full-time employees. The firm is focused on developing oral therapies to patients with unmet medical needs in immunology and oncology. The company uses its Tailored Covalency platform to design and develop reversible covalent and irreversible covalent, small molecule inhibitors. Its pipeline includes PRN1008, PRN1371 and PRN2246. PRN1008 drug candidate is designed for the treatment of chronic immunological disorders. PRN2246 is an irreversible covalent BTK inhibitor for the treatment of multiple sclerosis (MS), and other central nervous system (CNS) diseases. PRN1008 is also being developed for the treatment of multiple autoimmune diseases, such as pemphigus. PRN1371 is an inhibitor of Fibroblast Growth Factor Receptor (FGFR), designed for the treatment of solid tumors. The firm also focuses on developing oral immunoproteasome inhibitor for the treatment of inflammation and autoimmune disorders.